UK’s NHS Facing Major Leadership Shake-Up
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
Address: Department for Business, Innovation & Skills, 1 Victoria Street, London SW1H 0ET, United Kingdom
Tel: +44 (0)20 7215 5000
Web: https://www.gov.uk/government/organisations/department-for-business-innovation-skills
The Department for Business, Innovation and Skills (BIS) is building a dynamic and competitive UK economy by: creating the conditions for business success; promoting innovation, enterprise and science; and giving everyone the skills and opportunities to succeed. To achieve this it will foster world-class universities and promote an open global economy. BIS – Investing in our future
The Department for Business, Innovation and Skills (BIS) has an important role at the heart of government as the ‘department for growth’.
That’s why BIS is leading work across government to develop a more balanced and sustainable model for growth. We are building on the Strategy for Sustainable Growth, published in July, with a view to publishing a White Paper in the autumn.
British business can’t prosper while the risk of a debt crisis hangs over the economy. Striking the right balance between making savings and promoting sustainable growth is crucial. This is not just about cuts, but about creating a stable environment that enables businesses to invest and grow with confidence.
We aim to create an enterprise culture where everyone with talent is inspired to turn ideas into successful enterprises and get rid of unnecessary barriers that can stifle growth.
There are three key ways BIS is contributing:
x promoting business and innovation;
x creating a highly-skilled workforce and;
x promoting free and open markets.
The Government, led by BIS, wants to rebalance the economy. This means moving away from an economy reliant on debt to a sustainable one that is greener and more technologically advanced. And it means creating opportunities which are spread more across the regions, and through those sectors where the UK is strong and can add real value.
In a world where there is less money, the role of the state needs to change to get a smarter balance of public and private investment in the economy. We will refocus public spending on those areas where it has the greatest impact on growth and make sure that wider Government policy protects and supports the business environment.
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
Just one year after the UK government published its Life Science Vision, outlining the ambitions of the government and the life science sector for the next 10 years, the Association…
After a tumultuous year, AstraZeneca is creating a standalone vaccine unit and will begin to charge for its COVID-19 vaccine shot, having previously provided it at cost. PharmaBoardroom looks back…
The latest news from UK pharma, including AstraZeneca’s decision to create a dedicated business unit for its COVID-19 vaccines, GSK’s raised profits forecast, and CDMO Almac’s move to create over…
Cyril Titeux, senior VP mid-sized markets EMEA & strategic leader at Janssen, argues that the current focus of many health systems on efficiency, streamlining, and reducing spending is leaving them…
British pharmaceuticals giant, GSK, one of the UK’s largest companies by market capitalization, is once again finding itself under the spotlight as analysts and shareholders alike continue to query the…
Kathy Pritchard-Jones, Professor of Paediatric Oncology at University College London (UCL) and President of the International Society of Paediatric Oncology (SIOP) discusses the latest advancements in childhood cancer treatment, the…
Zack Pemberton-Whiteley, CEO of UK-based blood cancer charity Leukaemia Care, discusses the importance of patient and patient organizations’ involvement in the decision-making process for therapy appraisals, the use of HTA,…
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and fallout of the EU/AstraZeneca vaccine dispute and why the twin forces of…
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma giant; CDMO Sterling’s latest acquisition; and calls for a national registry to…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical company successfully listed on NASDAQ, raising over USD 30 million. Founded…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left…
See our Cookie Privacy Policy Here